Otonomy (NASDAQ:OTIC) Now Covered by StockNews.com
Otonomy (NASDAQ:OTIC) Now Covered by StockNews.com
Analysts at StockNews.com began coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report issued on Friday. The firm set a "hold" rating on the biopharmaceutical company's stock.
股票新聞分析師開始對股票的報導 性 (納斯達克:奧迪 — 獲得評級) 在上週五發布的研究報告中。該公司對生物製藥公司的股票設定了「持有」評級。
Separately, Piper Sandler lowered shares of Otonomy from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $3.00 to $0.50 in a research note on Thursday, October 13th.
另外,派珀·桑德勒(Piper Sandler)在 10 月 13 日(星期四)的一份研究報告中,將 Otonomy 的股票從「超重」評級降至「中性」評級,並將該股票的目標價從 3.00 美元降至 0.50 美元。
Otonomy Price Performance
Otonomy 的價格表現
Shares of NASDAQ OTIC opened at $0.11 on Friday. The firm has a market cap of $7.40 million, a PE ratio of -0.14 and a beta of 1.55. Otonomy has a 12-month low of $0.06 and a 12-month high of $2.59. The company's fifty day simple moving average is $0.10 and its 200 day simple moving average is $0.25.
納斯達克奧迪的股票上週五以 0.11 美元開盤。該公司的市值為 740 萬美元,私募股權比率為 -0.14,測試值為 1.55。Otonomy 有一個 12 個月低點 0.06 美元和 12 個月的高位 2.59 美元。該公司的五十天簡單移動平均線為 0.10 美元,其 200 天的簡單移動平均線為 0.25 美元。
Institutional Trading of Otonomy
Otonomy 的機構交易
Several institutional investors and hedge funds have recently made changes to their positions in OTIC. Point72 Asset Management L.P. purchased a new stake in shares of Otonomy in the third quarter valued at about $1,621,000. Lynx1 Capital Management LP increased its holdings in Otonomy by 7,609.6% during the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after buying an additional 2,282,880 shares during the last quarter. Requisite Capital Management LLC purchased a new stake in Otonomy during the third quarter worth about $44,000. Dimensional Fund Advisors LP increased its holdings in Otonomy by 17.7% during the first quarter. Dimensional Fund Advisors LP now owns 841,694 shares of the biopharmaceutical company's stock worth $2,020,000 after buying an additional 126,747 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in Otonomy by 129.2% during the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 80,153 shares during the last quarter. Hedge funds and other institutional investors own 41.23% of the company's stock.
幾家機構投資者和對沖基金最近更改了他們在奧迪的倉位。72 點資產管理有限責任公司在第三季度購買了一股新的 Otonomy 股份,價值約為 1,621,000 美元。Lynx1 資本管理有限公司在第三季度增加了其在 Otonomy 的持有量 7,609.6%。Lynx1 資本管理有限公司在上一季度額外購買 2,282,880 股股票後,擁有該生物製藥公司股票價值 682,000 美元的 2,312,880 股股份。必要資本管理有限責任公司在第三季度購買了 Otonomy 的新股份,價值約為 44,000 美元。維基金顧問有限公司在第一季度將其在 Otonomy 的持有量增加了 17.7%。維基金顧問 LP 在上一季度額外購買 126,747 股股票後,現在擁有該生物製藥公司的 841,694 股股價值 2,020,000 美元。最後, 兩西格瑪投資 LP 在第三季度增加了其在 Otonomy 的持有 129.2%.兩個西格瑪投資 LP 現在擁有 142,183 股的生物製藥公司的股票,價值 42,000 美元在上一個季度購買了 80,153 股後。對沖基金和其他機構投資者擁有公司股票的 41.23%。
About Otonomy
關於「音樂」
(Get Rating)
(取得評分)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Otonomy, Inc 是一家生物製藥公司。從事神經病學治療藥物的開發。該公司的產品線包括奧替維克斯(地塞米松)梅尼爾氏病,奧替普利(環丙沙星懸浮液)急性中耳炎,帶管(AOMT),OTO-313(加基克列定)耳鳴,OTO-413(BDNF)隱性聽力損失,OTO-510(耳保護劑)防止耳朵重度損失(CIPHL),致聽力損失(CIHL)嚴重聽力損失(CIHL)。OTO-6XX
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- The Uptrend in PepsiCo Stays Intact
- 3 Outperforming Stocks Partying Like It's 2020
- Disney Stock and The Bob Iger Effect
- Why Do Penny Stocks Often Crash After Rallies?
- This Is Why You Shouldn't Be So Happy About The Labor Data
- 免費獲取有關 OTONNOMY 的研究報告
- 百事公司的上升趨勢保持完好無損
- 3 表現優於股票,像 2020 年一樣聚會
- 迪士尼股票和鮑勃·伊格爾效應
- 為什麼細價股經常在集會後崩潰?
- 這就是為什麼您不應該對勞動力數據感到如此高興
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。